Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa

AIDS Research and Human Retroviruses

Volumn 20, Issue 10, 2004, Pages 1053-1056

  Nachega, J B ^a   Stein, D M ^a   Lehman, D A ^a   Hlatshwayo, D ^b   Mothopeng, R ^b   Chaisson, R E ^a,c   Karstaedt, A S ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH BEHAVIOR; HEALTH EDUCATION; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; SEXUALITY; SOUTH AFRICA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SOUTH AFRICA; VIRAL LOAD;

EID: 6344241646     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2004.20.1053     Document Type: Article

References (10)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13): 853-860.
2. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, and Salaniponi FM: Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001;358(9279):410-414.
3. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133(1):21-30.
4. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al.: Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15(9): 1181-1183.
5. Lucas GM, Chaisson RE, and Moore RD: Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: A 5-year cohort study. J Acquir Immune Defic Syndr 2003;33(3):321-328.
6. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al.: Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000;12(3):255-266.
7. Orrell C, Bangsberg DR, Badri M, and Wood R: Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003;17(9):1369-1375.
8. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al.: Assessment of a pilot antiretroviral drug therapy programme in Uganda: Patients' response, survival, and drug resistance. Lancet 2002;360(9326):34-40.
9. Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, Faye MA, et al.: The Senegalese government's highly active antiretroviral therapy initiative: An 18-month follow-up study. AIDS 2002;16(10):1363-1370.
10. Lucas GM, Chaisson RE, and Moore RD: Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131(2): 81-87.